Estimaciones de analistas de Wall Street para Nutriband Inc. (NTRB): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Consenso de analistas
| Compra fuerte | 0 |
| Compra | 1 |
| Mantener | 0 |
| Venta | 0 |
| Venta fuerte | 0 |
| Analistas totales | 1 |
| Calificación media (1-5) | 1.00 |
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-12-07 | |||
| 2026-09-04 | $-0.07 | ||
| 2026-06-11 | $-0.10 | $-1.89 | +94.7% |
| 2026-04-29 | $-0.04 | $-1.89 | +97.9% |
| 2025-12-16 | $-0.12 | $-2.13 | +94.4% |
| 2025-09-09 | $-2.12 | $-0.17 | -1147.1% |
| 2025-05-30 | $-0.12 | $-0.13 | +7.7% |
| 2025-04-28 | $-0.50 | $-0.12 | -316.7% |
Ratios de valoración
| Precio / Valor contable | 16.06 |
| EV / EBITDA | -10.13 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | 0 | 0 | $245285 | $370647 | $943702 | $1.4M | $2.1M | $2.1M | $2.1M | $2.0M |
| Coste de Ventas | 0 | 0 | $288301 | $549107 | $582378 | $917844 | $1.3M | $1.2M | $1.4M | $1.5M |
| Beneficio Bruto | 0 | 0 | -$43016 | -$178460 | $361324 | $504310 | $750409 | $862105 | $699302 | $566308 |
| I+D | 0 | 0 | 0 | 0 | 0 | $411383 | $982227 | $2.0M | $3.1M | $1.9M |
| Generales y Administrativos | $151260 | $171946 | $3.3M | $1.8M | $3.0M | $4.0M | $3.9M | $3.8M | $4.3M | $7.0M |
| Gastos Operativos | $151260 | $171946 | $3.3M | $1.8M | $3.0M | $4.4M | $4.9M | $5.7M | $7.4M | $8.9M |
| Beneficio Operativo | -$151260 | -$171946 | -$3.3M | -$2.0M | -$2.6M | -$3.9M | -$4.1M | -$4.9M | -$6.7M | -$8.3M |
| EBITDA | 0 | -$2.7M | -$3.3M | -$2.6M | -$2.5M | -$5.7M | -$4.1M | -$5.1M | -$10.2M | -$8.0M |
| Gastos por Intereses | 0 | 0 | 0 | $73413 | $280686 | $118421 | $8289 | $75815 | $21407 | $22535 |
| Beneficio Antes de Impuestos | -$151260 | -$2.7M | -$3.3M | -$2.7M | -$2.9M | -$6.2M | -$4.5M | -$5.5M | -$10.5M | -$8.2M |
| Impuestos | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Neto | -$151260 | -$2.7M | -$3.3M | -$2.8M | -$3.2M | -$8.4M | -$4.8M | -$5.5M | -$10.5M | -$8.2M |
| BPA | $-0.03 | $-0.48 | $-0.53 | $-0.44 | $-0.48 | $-1.06 | $-0.57 | $-0.69 | $-0.99 | $-2.58 |
| BPA Diluido | $-0.03 | $-0.48 | $-0.53 | $-0.44 | $-0.48 | $-1.06 | $-0.57 | $-0.69 | $-0.99 | $-2.58 |
| Acciones en Circulación (Diluidas) | $6.1M | $5.6M | $6.2M | $6.3M | $6.7M | $7.9M | $8.5M | $8.0M | $10.6M | $11.6M |
Precio
| Precio | $7.04 |
| Capitalización | $86M |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: ACET · ACRV · ADAG · CRVO · FBIO · GANX · LITS
Explorar sector: Healthcare · Biotechnology
Más secciones de NTRB: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones